DK3200791T3 - Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister - Google Patents
Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister Download PDFInfo
- Publication number
- DK3200791T3 DK3200791T3 DK15845610.3T DK15845610T DK3200791T3 DK 3200791 T3 DK3200791 T3 DK 3200791T3 DK 15845610 T DK15845610 T DK 15845610T DK 3200791 T3 DK3200791 T3 DK 3200791T3
- Authority
- DK
- Denmark
- Prior art keywords
- intermediates
- preparation
- methods
- c5ar antagonists
- c5ar
- Prior art date
Links
- 101150009981 C5AR1 gene Proteins 0.000 title 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057107P | 2014-09-29 | 2014-09-29 | |
| PCT/US2015/052697 WO2016053890A1 (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3200791T3 true DK3200791T3 (da) | 2020-05-25 |
Family
ID=55583729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15845610.3T DK3200791T3 (da) | 2014-09-29 | 2015-09-28 | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9745268B2 (da) |
| EP (2) | EP3682879B1 (da) |
| JP (1) | JP6898229B6 (da) |
| KR (2) | KR20230149873A (da) |
| CN (2) | CN113121415A (da) |
| AU (2) | AU2015324111B2 (da) |
| BR (1) | BR112017006232B1 (da) |
| CA (2) | CA3220371A1 (da) |
| DK (1) | DK3200791T3 (da) |
| ES (2) | ES2802428T3 (da) |
| IL (1) | IL251061B (da) |
| MA (1) | MA52308A (da) |
| MX (2) | MX368492B (da) |
| NZ (2) | NZ767823A (da) |
| PL (1) | PL3200791T3 (da) |
| PT (1) | PT3200791T (da) |
| RU (1) | RU2712233C2 (da) |
| SG (1) | SG11201702185UA (da) |
| WO (1) | WO2016053890A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
| US9126939B2 (en) * | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| MA52308A (fr) * | 2014-09-29 | 2021-02-24 | Chemocentryx Inc | Procédés et intermédiaires pour la préparation d'antagonistes c5ar |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| JP2021501175A (ja) | 2017-10-30 | 2021-01-14 | ケモセントリックス，インコーポレイティド | 免疫調節剤としての重水素化化合物 |
| WO2019236820A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
| IL283450B1 (en) | 2018-11-30 | 2024-02-01 | Chemocentryx Inc | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses |
| KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
| CN114641289A (zh) * | 2019-11-08 | 2022-06-17 | 凯莫森特里克斯股份有限公司 | 补体成分C5a受体的游离碱晶型 |
| TW202128623A (zh) | 2019-11-08 | 2021-08-01 | 美商卡默森屈有限公司 | 補體成分Ｃ５ａ受體之鹽形式 |
| WO2021092286A1 (en) | 2019-11-08 | 2021-05-14 | Chemocentryx, Inc. | Amorphous form of a complement component c5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技（苏州）有限公司 | 一种Avacopan及其中间体的制备方法 |
| CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
| WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| CN1261098C (zh) | 1998-08-28 | 2006-06-28 | 西奥斯股份有限公司 | p38－α激酶的抑制剂 |
| RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
| AU2001259511A1 (en) | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
| ES2353077T3 (es) | 2000-08-10 | 2011-02-25 | Mitsubishi Tanabe Pharma Corporation | Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos. |
| US7855297B2 (en) | 2000-09-14 | 2010-12-21 | Mitsubishi Tanabe Pharma Corporation | Amide derivatives and medicinal use thereof |
| YU23503A (sh) | 2000-09-29 | 2006-03-03 | Neurogen Corporation | Mali molekuli kao modulatori receptora c5a visokog afiniteta |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| DE10231783A1 (de) | 2001-07-19 | 2003-03-20 | Luk Lamellen & Kupplungsbau | System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges |
| CN100391537C (zh) | 2001-08-17 | 2008-06-04 | 建南德克公司 | 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂 |
| TWI265164B (en) | 2001-09-21 | 2006-11-01 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| CA2479930A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| AU2003225971A1 (en) | 2002-03-28 | 2003-10-13 | Yang Gao | Substituted biaryl amides as c5a receptor modulators |
| AU2003220553A1 (en) | 2002-03-29 | 2003-10-20 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| CA2504941C (en) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| CA2528652A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
| EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| NZ561613A (en) | 2005-02-18 | 2010-12-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| JP5374157B2 (ja) | 2005-11-24 | 2013-12-25 | ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ | （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物 |
| EP4316465A3 (en) | 2006-03-15 | 2024-04-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| US8198266B2 (en) | 2006-10-31 | 2012-06-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of an EGFR antagonist for the treatment of glomerolonephritis |
| WO2009004650A1 (en) | 2007-06-29 | 2009-01-08 | Torrent Pharmaceuticals Ltd. | Novel substituted piperidones as hsp inducers |
| WO2010019210A2 (en) | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| EP2894165B1 (en) | 2008-11-10 | 2023-01-04 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| US9126939B2 (en) * | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| BR112014031375A2 (pt) | 2012-06-20 | 2017-06-27 | Novartis Ag | moduladores da série de reação complementar e usos dos mesmos |
| CN105392803B (zh) | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
| MA52308A (fr) * | 2014-09-29 | 2021-02-24 | Chemocentryx Inc | Procédés et intermédiaires pour la préparation d'antagonistes c5ar |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| CA3019137A1 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | Soluble c5ar antagonists |
| CN116635075A (zh) | 2020-12-21 | 2023-08-22 | 坎莫森特里克斯公司 | 使用c5a抑制剂治疗c3肾小球病 |
-
2015
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3200791T3 (da) | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister | |
| IL292094A (en) | Neoantigens and methods for using them | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| HK1250990A1 (zh) | 凝血因子xi抗體及使用方法 | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3227342T3 (da) | Proteinøs heterodimer og anvendelse deraf | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
| CR20180296A (es) | ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| IL250428A0 (en) | Anti-ox40l antagonist antibodies and methods of using them | |
| BR112016024803A2 (pt) | suportes abrasivos e métodos de sua formação | |
| DK3137873T3 (da) | Viscometer and methods of use thereof | |
| DK3018383T3 (da) | Afslutning af styrkeelementer i dybhavskabler | |
| BR112017012240A2 (pt) | métodos de preparação de composições contendo alcaloides e suas utilizações |